AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00866840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: 100 mg orally twice daily
Study NCT03362255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization with different speed of injection
Study NCT00808808 — intervention group
Intervention type: BIOLOGICAL
Intervention: Choice of TIV or FluMist with baseline advertisement
Description: An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
Study NCT00808808 — intervention group
Intervention type: OTHER
Intervention: Choice of TIV or FluMist with enhanced advertisement and incentives
Description: An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
Study NCT00808808 — intervention group
Intervention type: BIOLOGICAL
Intervention: Control - Usual care offering TIV only with baseline advertisement
Description: A control arm of usual care offering TIV with baseline advertisement
Study NCT00864448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril10 mg Capsules, single dose
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study NCT00864448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atlace® 10 mg capsules, single dose
Description: B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
Study NCT02907346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement for wearing CGM
Description: The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
Study NCT03720704 — intervention group
Intervention type: DEVICE
Intervention: GORE VIABAHN VBX Balloon Expandable Endoprosthesis
Description: GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.
Study NCT01781572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 will be administered orally once daily
Study NCT01781572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 will be administered orally twice daily
Study NCT03882684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: In-situ imprinting detection
Description: The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.
Study NCT00344123 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tipranavir/Ritonavir
Description: On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.
Study NCT00344123 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r..
Study NCT00780494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous 15 mg/kg
Study NCT00780494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6, Intravenously Day 1 every 21 days
Study NCT00780494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 850mg/m2, Orally twice daily days 1-14 every 21 days.
Study NCT03808675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic walking
Description: The investigators will use self-administered continuous walking exercise at a moderate intensity level, defined as 40-59% of heart rate reserve or 64-77% of heart rate at gas exchange threshold (HRGET) by ACSM as in the investigators' preliminary study (PMID: 24991037 PMCID: PMC4132568). The HRGET will be determined as the heart rate at VO2max during graded cycle ergometry. The total duration of the exercises will be 150 min/week per 2008 Physical Activity Guidelines for Americans and American Heart Association recommendations, conducted in three 50 min sessions. The aerobic walking intervention will take place outdoors (e.g., trails, sidewalks, parks) or indoors (e.g., track in a local gym or a mall) depending on the preferences of the subject and weather. Session duration will be 20 min the first week and will be advanced by 5 min per week over 6 weeks.
Study NCT03808675 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care with PD specific health education
Description: In this study, patients will receive their usual medical treatment for motor and non-motor symptoms from their~primary neurologist. The investigators will use a streamlined form of PD specific health education prepared by the VA: My Parkinson's Story, which consists of a series of short videos prepared by the VA PADRECCs addressing various aspects of PD. These 6-12 minutes long videos are freely available on YouTube. The investigators can also provide them on a CD if subjects desire. They start with a patient testimony about the topic of the episode, followed by comments of experts in the field. The title of the episodes are: Early Parkinson's, Medications, Exercise, Memory, Visual Disturbances, Depression, Sleep, Speech and Swallowing, Impulsive Behaviors, Driving, Pain, Dyskinesias, Deep Brain Stimulation, Advanced Parkinson's Disease, Falls, The Caregiver, Hospitalization, Genetics, Environmental Exposure, Atypical Parkinsonism
Study NCT02693665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAmily CEntered Advance Care Planning for Teens with Cancer
Description: 3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
Study NCT03972488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: Lutathera is a sterile radiopharmaceutical supplied as a ready-to-use solution for infusion containing 177Lu-DOTA0-Tyr3-octreotate as a drug substance with a volumetric activity of 370 MBq/mL at reference date and time (calibration time). Each Lutathera infusion continued for 30 min.
Study NCT03972488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutathera
Description: Lutathera is a sterile radiopharmaceutical supplied as a ready-to-use solution for infusion containing 177Lu-DOTA0-Tyr3-octreotate as a drug substance with a volumetric activity of 370 MBq/mL at reference date and time (calibration time). Each Lutathera infusion continued for 30 min.
Study NCT03972488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)
Description: Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes.
Study NCT03972488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% Lys-Arg sterile amino acid solution
Description: Participants who received Lutathera were administered a concomitant 2.5% Lys-Arg solution for kidney protection, with each Lutathera dose. The 2.5% Lys-Arg solution was administered intravenously for 4 hours (infusion rate: 250 ml/h); the infusion was to start 30 minutes prior to the start of the Lutathera infusion and continue during (30 min) and up to at least 3 hours after the Lutathera infusion.
Study NCT03972488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose 60 mg octreotide long-acting repeatable
Description: Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes.
Study NCT01394263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex goserelin implant
Description: goserelin implant injection.
Study NCT02580188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
Study NCT03139565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-dose Influenza Vaccine
Description: This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
Study NCT03139565 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard 2016-2017 Flu vaccine
Description: The intramuscular preparation of the vaccine used for the control group will be the Standard influenza vaccine made available by public health. The intramuscular dose (standard 0.5 mL) will contain 15 microgram antigen from each strain and delivered in the deltoid muscle by trained personnel.
Study NCT01434459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine with TheraSphere
Description: Gemcitabine dose will be escalated and combined with therasphere.
Study NCT01360632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712 + ADT
Description: Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
Study NCT01360632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo + ADT
Description: Placebo + FDA Approved Antidepressant (ADT)
Study NCT01360632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + ADT
Description: Placebo + FDA Approved Antidepressant (ADT)
Study NCT01986790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plain Language
Study NCT01986790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plain Language + Visuals
Study NCT01986790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plain Language + Narratives
Study NCT00069407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy
Description: Electroconvulsive therapy
Study NCT04080882 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA dose 1
Description: Treatment of platysmal bands
Study NCT03529513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mini International Neuropsychiatric Interview
Description: The Mini International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview that was developed as a simple tool to assist clinicians to conduct psychiatric diagnoses according to the DSM-IV and International Statistical Classification of Diseases and Related Health Problems tenth revision (ICD-10) criteria.
Study NCT03529513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hamilton Rating Scale for Depression - 17 Item
Description: The clinician-administered Hamilton Depression Rating Scale (also known as the HAM-D) is the most widely used depression assessment scale . The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. There are numerous versions with varying lengths that include the HDRS21, HDRS24, and HDRS29. This study will utilize the HDRS17 (HAMD-17) version.
Study NCT04665219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBM-based text messages
Description: The intervention in the test group will consist of a set of text messages developed based on the HBM to be sent to the parents regularly in the following 48 weeks.~During the first 24 weeks, parents will receive a text message (and feedback if deemed appropriate) each week. In the next 24 weeks, the parents will receive a text message every 4 weeks, altogether 30 messages will be sent to the parents. All messages will be sent to the parents individually through free mobile App by a research assistant.
Study NCT04665219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard text message
Description: Parents in the control group will receive an oral health education pamphlet produced by the Oral Health Education Division in the Department of Health, the Government of Hong Kong SAR. In order to maintain a double-blind design in the present study, the pamphlet will be distributed in an electronic form and sent via a text message.
Study NCT04051671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Dual Active/sham tDCS will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy. Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 2 weeks. The two experiments will be performed in random order for each subject.
Study NCT04051671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Dual Active/sham tDCS will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy. Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 2 weeks. The two experiments will be performed in random order for each subject.
Study NCT04367545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: Saliva collection will be done in addition to standard diagnosis collection (nasopharyngeal collection using swab)
Study NCT01521520 — intervention group
Intervention type: DRUG
Intervention: ferumoxytol
Description: Ferumoxytol at a dose of between 1 and 6 mg iron/kg body weight (maximum 510 mg/injection) will be administered via intravenous injection. Ferumoxytol will be administered with each series of MRIs.
Study NCT03667222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline topical gel
Description: Once daily administration of BPX-04 minocycline gel for 12 weeks
Study NCT03667222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical gel vehicle
Description: Once daily administration of BPX-04 gel vehicle for 12 weeks
Study NCT02842710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GeneXpert®
Description: Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
Study NCT06670144 — intervention group
Intervention type: OTHER
Intervention: Dietary pattern
Description: (regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan; Mediterranean diet)
Study NCT06670144 — intervention group
Intervention type: OTHER
Intervention: Alcohol intake
Description: (Frequency and intake of beer, wine, sherry, and spirits were collected by asking the number of specified units (pints, glasses or measures) of each type of alcoholic beverage (beer or cider, wine, sherry or fortified wines, and spirits) per week.)
Study NCT06670144 — intervention group
Intervention type: OTHER
Intervention: Fruit and vegetables intake
Description: (Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire)
Study NCT06670144 — intervention group
Intervention type: OTHER
Intervention: Tea consumption
Description: (Intake of tea from food frequency questionnaire)
Study NCT06670144 — intervention group
Intervention type: OTHER
Intervention: Coffee consumption
Description: (Intake of caffeinated coffee and decaffeinated coffee from food frequency questionnaire)
Study NCT06670144 — intervention group
Intervention type: OTHER
Intervention: Fish intake
Description: (Intake of fish from food frequency questionnaire)
Study NCT06670144 — intervention group
Intervention type: OTHER
Intervention: Meat intake
Description: (Intake of red meat, processed meat, and poultry from food frequency questionnaire)
Study NCT06670144 — intervention group
Intervention type: OTHER
Intervention: Vitamin D intake
Description: (Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake)
Study NCT04080882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment of platysmal bands
Study NCT04080882 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA dose 2
Description: Treatment of platysmal bands
Study NCT04080882 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA dose 3
Description: Treatment of platysmal bands
Study NCT04182139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching Exercise
Description: Each intervention group received a different duration and intensity of static stretching exercise protocol.
Study NCT00707915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Benzodiazepine (listed out below)
Description: The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.~All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks.
Study NCT03548207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-68284528
Description: JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
Study NCT02270983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide 145 micrograms
Study NCT02270983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide 290 micrograms
Study NCT02270983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT04651283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional seat group
Description: Each child in the control group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~1. Building towers and shapes with different textures weights and bright colors.~2. Inserting different shapes in the correct hole.~3. Dropping pellets.~4. Stringing beads.~5. Copying square and triangle.~6. Opening the bottle and close it.~7. Folding and Crumpling paper.~8. Cutting paper by scissors.~9. Tracing line and connecting dots.~10. Reaching above the level of shoulder.~11. Reaching across the midline.~12. Squeezing water out of a sponge.~13. Buttoning and unbuttoning button.~14. Playing clapping games.~15. Turning pages in a book.~16. Lacing string.~17. Picking up a small piece of food and bringing it into the palm.~18. Moving a penny from the palm to the fingers.~19. Removing socks.~20. Brush the teeth.
Study NCT04651283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive seating equipment group
Description: Each child in the study group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~1. Building towers and shapes with different textures weights and bright colors.~2. Inserting different shapes in the correct hole.~3. Dropping pellets.~4. Stringing beads.~5. Copying square and triangle.~6. Opening the bottle and close it.~7. Folding and Crumpling paper.~8. Cutting paper by scissors.~9. Tracing line and connecting dots.~10. Reaching above the level of shoulder.~11. Reaching across the midline.~12. Squeezing water out of a sponge.~13. Buttoning and unbuttoning button.~14. Playing clapping games.~15. Turning pages in a book.~16. Lacing string.~17. Picking up a small piece of food and bringing it into the palm.~18. Moving a penny from the palm to the fingers.~19. Removing socks.~20. Brush the teeth.
Study NCT00918632 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> B -> C. Each of these treatments will be separated by a 7 day washout period.
Study NCT02038673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5878
Description: oral
Study NCT00918632 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> C -> B. Each of these treatments will be separated by a 7 day washout period.
Study NCT00918632 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> C -> A. Each of these treatments will be separated by a 7 day washout period.
Study NCT00918632 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> A -> C. Each of these treatments will be separated by a 7 day washout period.
Study NCT02094352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Infusion + Epidural Infusion
Description: The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.